Entering text into the input field will update the search result below

Homology Medicines Files For U.S. IPO


  • Homology Medicines wants to raise $100 million in an IPO, although the final amount may change.
  • The firm is developing genetic delivery and analysis technologies that promise to improve results with increased safety.
  • FIXX is still in pre-clinical stage, so the IPO is ultra-high-risk for investors.
  • I'll provide a final opinion when we learn more details about IPO terms.

Quick Take

Homology Medicines (NASDAQ:FIXX) intends to sell shares of its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.

The firm is a genetic medicines company focused on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Through a new multidimensional technology platform, the company is focused on moving beyond current limitations of gene editing and gene therapy approaches.

FIXX is developing a promising technology to reduce genetic editing errors, but the firm is not even at Phase 1 safety trial stage yet.


Bedford, MA-based Homology Medicines was founded in 2015 ‘to transform the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.’

Management is headed by President and CEO Arthur Tzianabos, who has been with the firm since 2016. Tzianabos was previously President and CSO of OvaScience and also served in various upper-level positions with Shire.

The company’s gene editing platform, AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination), harnesses the naturally occurring process of homologous recombination to correct gene mutations. Through this platform, Homology is focused on developing product candidates to treat monogenic diseases in the liver, CNS, bone marrow, lung and the eye.

Investors in Homology include Deerfield, 5AM Ventures, ARCH Venture Partners, Novartis (NVS) and TLS Beta, among others.


Homology Medicines uses a gene editing approach that begins with designing homology sequence arms which are highly specific to a region of the human genome. This results in a permanent therapeutic correction in the DNA upon cell delivery. The technology is based on the discovery of a novel class of human-derived adeno-associated virus [AAV] vectors. These vectors can be used to achieve efficient in vivo and ex vivo gene editing and gene

An enhanced version of this article including commentary on the IPO is available on my Seeking Alpha Marketplace research service, IPO Edge. I write in-depth research about U.S. IPOs and members learn the latest IPO research, news, market trends and industry analysis. Start with a Free Trial.

This article was written by

Donovan Jones profile picture

Donovan Jones is a research specialist with 15 years of experience identifying opportunities for IPOs and software companies.

He also leads the investing group

IPO Edge

which offers: actionable information on growth stocks through first look S-1 filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.

Learn more


Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About FIXX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on FIXX

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.